Lack of effect of cimetidine on action of phenprocoumon. 1982

J Harenberg, and R Zimmermann, and C Staiger, and J X de Vries, and E Walter, and E Weber

In patients on oral warfarin, nicoumalone and phenindione an increase in the anticoagulant effect has been described during concomitant treatment with cimetidine. Therefore the effect of cimetidine on the steady state dynamics of phenprocoumon has been investigated in ten outpatients. No change in the anticoagulant effect of phenprocoumon was observed during or after two weeks on cimetidine, as measured by the thrombotest coagulation method, prothrombin time, fibrinopeptide A concentration and plasma phenprocoumon level. The data show that cimetidine does not interact with the metabolism of phenprocoumon in contrast to warfarin. Thus, phenprocoumon maintenance therapy when combined with concomitant cimetidine treatment can be considered not to carry an increased risk of haemorrhagic complications.

UI MeSH Term Description Entries
D010314 Partial Thromboplastin Time The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy. Activated Partial Thromboplastin Time,Cephalin-Kaolin Coagulation Time,Kaolin-Cephalin Coagulation Time,Thromboplastin Time, Partial,Coagulation Time, Cephalin-Kaolin,Cephalin Kaolin Coagulation Time,Coagulation Time, Cephalin Kaolin,Coagulation Time, Kaolin-Cephalin,Kaolin Cephalin Coagulation Time
D010644 Phenprocoumon Coumarin derivative that acts as a long acting oral anticoagulant. Phenprocoumalol,Phenprocoumarol,Phenylpropylhydroxycumarinum,Falithrom,Liquamar,Marcoumar,Marcumar,Phenprogramma
D011517 Prothrombin Time Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS. Quick Test,Russell's Viper Venom Time,Thrombotest,Russell Viper Venom Time,Russells Viper Venom Time,Prothrombin Times,Test, Quick,Time, Prothrombin,Times, Prothrombin
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006146 Guanidines A family of iminourea derivatives. The parent compound has been isolated from mushrooms, corn germ, rice hulls, mussels, earthworms, and turnip juice. Derivatives may have antiviral and antifungal properties.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
D015110 4-Hydroxycoumarins Substances found in many plants, containing the 4-hydroxycoumarin radical. They interfere with vitamin K and the blood clotting mechanism, are tightly protein-bound, inhibit mitochondrial and microsomal enzymes, and are used as oral anticoagulants. 4 Hydroxycoumarins

Related Publications

J Harenberg, and R Zimmermann, and C Staiger, and J X de Vries, and E Walter, and E Weber
January 1989, Dermatologica,
J Harenberg, and R Zimmermann, and C Staiger, and J X de Vries, and E Walter, and E Weber
January 1993, European journal of clinical pharmacology,
J Harenberg, and R Zimmermann, and C Staiger, and J X de Vries, and E Walter, and E Weber
May 1981, Drug intelligence & clinical pharmacy,
J Harenberg, and R Zimmermann, and C Staiger, and J X de Vries, and E Walter, and E Weber
November 1980, Lancet (London, England),
J Harenberg, and R Zimmermann, and C Staiger, and J X de Vries, and E Walter, and E Weber
February 1984, Archiv der Pharmazie,
J Harenberg, and R Zimmermann, and C Staiger, and J X de Vries, and E Walter, and E Weber
November 1989, Clinical pharmacology and therapeutics,
J Harenberg, and R Zimmermann, and C Staiger, and J X de Vries, and E Walter, and E Weber
August 1988, International journal of clinical pharmacology, therapy, and toxicology,
J Harenberg, and R Zimmermann, and C Staiger, and J X de Vries, and E Walter, and E Weber
March 1980, Southern medical journal,
J Harenberg, and R Zimmermann, and C Staiger, and J X de Vries, and E Walter, and E Weber
February 1987, Anesthesia and analgesia,
J Harenberg, and R Zimmermann, and C Staiger, and J X de Vries, and E Walter, and E Weber
November 1999, Journal of clinical pharmacology,
Copied contents to your clipboard!